title: A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia.
abstract: OBJECTIVE
  Although the importance of vascular endothelial growth factor receptor (VEGFR)-3 has been demonstrated in acute myeloid leukemia (AML), the role of VEGFR-3 in functioning natural killer (NK) cells remains largely unexplored. NK cells can destroy cancer cells by releasing the cytokine interferon (IFN)-γ, but NK cells in AML patients (AML NK cells) have low cytolytic activity. In the present study, we investigated whether lymphatic markers including VEGFR-3 are expressed on low-functioning AML NK cells and VEGFR-3 antagonist can restore expression of IFN-γ in NK cells.
  
  
  METHODS
  Samples from 67 de novo AML patients and 34 healthy donors were analyzed for lymphatic markers expression using RT-PCR, flow cytometry, and immunostaining. For the cytotoxicity assays, K562 cells and AML NK cells were used as target and effector cells, respectively. To block VEGFR-3, MAZ51 was added to NK cells, which were then subjected to FACS analysis.
  
  
  RESULTS
  Compared with NK cells from healthy donors (healthy NK cells), AML NK cells exhibited higher levels of VEGFR-3 and lower expression of IFN-γ. VEGFR-3-expressing AML NK cells were less potent than healthy NK cells in terms of killing K562 cells. The level of IFN-γ in AML NK cells was increased by VEGFR-3 antagonist treatment, indicating the functional relevance of VEGFR-3 in IFN-γ-secreting NK cells.
  
  
  CONCLUSIONS
  Collectively, our data suggest a relationship between VEGFR-3 and IFN-γ expression in NK cells and raise the possibility of advanced therapeutic approaches involving VEGFR-3 antagonist treatment prior to NK immune cell therapy in AML.
authors: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 505 Banpo 4-dong, Seocho-gu, Seoul, 137-701, Korea.
authors: Ji Yoon
authors: JY
authors: Lee
authors: Sohye
authors: S
authors: Park
authors: Donghyun Curt
authors: DC
authors: Kim
authors: Jae-Ho
authors: JH
authors: Yoon
authors: Seung Hwan
authors: SH
authors: Shin
authors: Woo-Sung
authors: WS
authors: Min
authors: Hee-Je
authors: HJ
authors: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007371:Interferon-gamma / Q000096:biosynthesis*; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000494:pharmacology; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D055815:Young Adult
chemical_list: C441602:3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one; D007211:Indoles; D009281:Naphthalenes; D007371:Interferon-gamma; D040321:Vascular Endothelial Growth Factor Receptor-3
references: Blood. 2010 Sep 9;116(10):1747-54
references: 20522712
references: J Invest Dermatol. 2006 Oct;126(10):2167-77
references: 16983326
references: Science. 2002 Mar 15;295(5562):2097-100
references: 11896281
references: J Clin Invest. 1989 Aug;84(2):451-7
references: 2788173
references: Trends Immunol. 2001 Nov;22(11):633-40
references: 11698225
references: Mol Immunol. 2005 Feb;42(4):501-10
references: 15607806
references: Nat Rev Immunol. 2007 Sep;7(9):703-14
references: 17717540
references: Transplantation. 2007 Nov 15;84(9):1082-91
references: 17998861
references: Blood. 2002 Mar 15;99(6):2179-84
references: 11877295
references: Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78
references: 17522591
references: Lymphat Res Biol. 2010 Sep;8(3):155-64
references: 20863268
references: Blood. 2010 Sep 2;116(9):1539-47
references: 20472832
references: Science. 2002 Jun 7;296(5574):1883-6
references: 11976409
references: J Immunol. 2000 Jan 1;164(1):217-22
references: 10605014
references: Science. 1981 Oct 2;214(4516):24-30
references: 7025208
references: Blood. 2005 May 1;105(9):3615-22
references: 15657183
references: Nat Med. 1997 Jul;3(7):730-7
references: 9212098
references: Leukemia. 2005 Dec;19(12):2215-22
references: 16224486
references: Blood. 2011 Apr 28;117(17):4467-75
references: 21364193
references: Circ Res. 2010 Sep 3;107(5):602-14
references: 20634489
references: Leukemia. 2012 Sep;26(9):2019-26
references: 22446501
references: J Exp Med. 1985 Jun 1;161(6):1464-82
references: 3159818
references: Blood. 2002 May 15;99(10):3661-7
references: 11986221
references: Blood. 2005 Jul 1;106(1):376-83
references: 15755898
references: Int J Cancer. 2004 Dec 20;112(6):986-93
references: 15386354
references: Leukemia. 1997 Nov;11(11):1878-86
references: 9369421
references: J Exp Med. 2001 Dec 3;194(11):1549-59
references: 11733570
references: Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3566-70
references: 7724599
references: N Engl J Med. 1971 Nov 18;285(21):1182-6
references: 4938153
references: Cancer Res. 2009 May 1;69(9):4010-7
references: 19383914
references: Leukemia. 1997 Aug;11(8):1234-7
references: 9264375
references: Am J Pathol. 2009 Oct;175(4):1709-21
references: 19779139
references: J Interferon Cytokine Res. 2006 Aug;26(8):568-74
references: 16881867
references: J Immunol. 2009 Aug 1;183(3):1767-79
references: 19587009
references: Immunity. 2011 Jan 28;34(1):96-107
references: 21256057